TSE:4503Pharmaceuticals
FDA’s PADCEV Keytruda Approval for All MIBC Patients Might Change The Case For Investing In Astellas Pharma (TSE:4503)
Pfizer and Astellas Pharma recently announced that the U.S. FDA approved PADCEV (enfortumab vedotin-ejfv) plus Keytruda as both neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer, regardless of cisplatin eligibility, based on positive Phase 3 EV-304 trial data versus standard gemcitabine-cisplatin chemotherapy.
This marks the first platinum-free regimen approved for all muscle-invasive bladder cancer patients, materially expanding the clinical and...